AT HOME PROFESSIONAL-ASSISTED REMOTE CANCER PATIENT MONITORING: A COMPREHENSIVE EVALUATION IN FRANCE
Author(s)
Louis Chillotti, PharmD1, Bertrand Mennecier, MD2, Anne Dory, PharmD3, Solenne Tauty, PharmD, MSc4, Céline Mascaux, MD5, Laure Guéroult-Accolas, Ms6, Guillaume Gaud, PharmD7, Bruno Detournay, MD, MBA8, Christelle Jouannaud, MD9, Philippe Barthélémy, MD10.
1Cytel, Oullins, France, 2Medical Oncology Department, University Hospital - Nancy, Nancy, France, 3Pharmacy Department, University Hospital– Strasbourg, Strasbourg, France, 4Stève Consultants, A Cytel Company, Oullins, France, 5Pulmonology Department, University Hospital- Strasbourg, Strasbourg, France, 6Patients en Réseau (Patient Association Patients en Réseau (Patient Association) - Paris, Paris, France, 7Cureety, Paris, Paris, France, 8Health Economist, Antony, France, 9Medical Oncology Department, Institut Godinot - Reims, Reims, France, 10Medical Oncology Department, University Hospital - Strasbourg, Strasbourg, France.
1Cytel, Oullins, France, 2Medical Oncology Department, University Hospital - Nancy, Nancy, France, 3Pharmacy Department, University Hospital– Strasbourg, Strasbourg, France, 4Stève Consultants, A Cytel Company, Oullins, France, 5Pulmonology Department, University Hospital- Strasbourg, Strasbourg, France, 6Patients en Réseau (Patient Association Patients en Réseau (Patient Association) - Paris, Paris, France, 7Cureety, Paris, Paris, France, 8Health Economist, Antony, France, 9Medical Oncology Department, Institut Godinot - Reims, Reims, France, 10Medical Oncology Department, University Hospital - Strasbourg, Strasbourg, France.
OBJECTIVES: The AKO@dom-PICTO program implemented a coordinated remote monitoring model connecting oncology and pharmaceutical hospital teams, community healthcare professionals, and patients through a digital platform. Depending on their clinical vulnerability, patients received support either from home care nurses (HCN) or from community pharmacists (CP). Allocation to each pathway was jointly decided by the hospital team and the patient. Both pathways were evaluated using qualitative and quantitative approaches.
METHODS: Evaluation criteria included medication adherence, adverse events, time spent by healthcare professionals, workloads, patients’ experience, and associated costs. Data was collected through surveys administered to patients and healthcare professionals and through the monitoring system. In addition, among AKO@dom-PICTO patients, those with ≥6 months follow-up were matched to controls from the French National Health Data System (with standard management) to assess AKO@dom-PICTO impact in a retrospective case-control analysis.
RESULTS: A total of 1,031 care pathways (618 HCN and 413 CP) were analyzed across 15 healthcare centers. Qualitative findings indicated that both pathways enhanced the involvement of community-based professionals, improved oncological follow-up, and facilitated the management of unplanned events without generating additional burden. The patient’s experience was significantly improved. The system facilitated the reporting of adverse events at an early stage, resulting in a lower incidence of Grade 3 or 4 events. Compared with matched controls, AKO@dom-PICTO patients showed lower treatment discontinuation rates (log-rank p-value = 0.0036) and shorter cumulative hospital stays following emergency visits (respectively 7.1 days (SD 7.4) vs 11.2 days (SD 11.9) p=0.007). Overall, 6-months healthcare expenditures were higher in monitored patients than in controls (p<0.001) mainly due to a longer treatment duration.
CONCLUSIONS: These results indicate that home-based remote monitoring for patients with cancer benefits from tailored support levels based on patient characteristics and suggests the relevance of developing this type of program in oncology.
METHODS: Evaluation criteria included medication adherence, adverse events, time spent by healthcare professionals, workloads, patients’ experience, and associated costs. Data was collected through surveys administered to patients and healthcare professionals and through the monitoring system. In addition, among AKO@dom-PICTO patients, those with ≥6 months follow-up were matched to controls from the French National Health Data System (with standard management) to assess AKO@dom-PICTO impact in a retrospective case-control analysis.
RESULTS: A total of 1,031 care pathways (618 HCN and 413 CP) were analyzed across 15 healthcare centers. Qualitative findings indicated that both pathways enhanced the involvement of community-based professionals, improved oncological follow-up, and facilitated the management of unplanned events without generating additional burden. The patient’s experience was significantly improved. The system facilitated the reporting of adverse events at an early stage, resulting in a lower incidence of Grade 3 or 4 events. Compared with matched controls, AKO@dom-PICTO patients showed lower treatment discontinuation rates (log-rank p-value = 0.0036) and shorter cumulative hospital stays following emergency visits (respectively 7.1 days (SD 7.4) vs 11.2 days (SD 11.9) p=0.007). Overall, 6-months healthcare expenditures were higher in monitored patients than in controls (p<0.001) mainly due to a longer treatment duration.
CONCLUSIONS: These results indicate that home-based remote monitoring for patients with cancer benefits from tailored support levels based on patient characteristics and suggests the relevance of developing this type of program in oncology.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HSD65
Topic
Health Service Delivery & Process of Care, Organizational Practices, Real World Data & Information Systems
Disease
Oncology